Our prior work published in this journal (2) demonstrated significantly increased autoantibodies against the GPCR angiotensin II receptor type 1 (AT1R) and endothelin receptor type A (ETAR) in patients with COVID-19 with unfavorable disease course compared to mild disease. The gene discussed is EDNRA; the disease is COVID-19.